Maves’ change of heart on ephedra
This article was originally published in The Tan Sheet
Executive Summary
Letter to FDA signed by former CHPA President and current American Medical Association Exec VP & CEO Michael Maves, MD, reiterates AMA's call for ephedrine alkaloid products to be removed from the market due to the number of related AERs. While Maves was at CHPA, the trade association opposed FDA's reliance on AERs in developing regulatory restrictions for ephedrine alkaloid products. However, in a Jan. 28 letter, Maves states "the number of AERs associated with dietary supplements containing ephedrine alkaloids is alarming"...